Leuthold Group LLC bought a new stake in VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) in the 3rd quarter, Holdings Channel.com reports. The firm bought 6,497 shares of the company’s stock, valued at approximately $711,000.
Several other institutional investors and hedge funds have also made changes to their positions in PPH. Fluent Financial LLC purchased a new position in VanEck Pharmaceutical ETF during the 2nd quarter worth approximately $4,264,000. Oppenheimer & Co. Inc. purchased a new stake in VanEck Pharmaceutical ETF in the third quarter valued at approximately $711,000. Adamsbrown Wealth Consultants LLC lifted its stake in VanEck Pharmaceutical ETF by 3.6% in the second quarter. Adamsbrown Wealth Consultants LLC now owns 154,114 shares of the company’s stock valued at $16,852,000 after buying an additional 5,303 shares during the last quarter. Independent Financial Group LLC purchased a new stake in VanEck Pharmaceutical ETF in the first quarter valued at approximately $532,000. Finally, Avior Wealth Management LLC acquired a new stake in shares of VanEck Pharmaceutical ETF in the third quarter valued at approximately $1,685,000.
VanEck Pharmaceutical ETF Trading Up 0.3%
Shares of PPH opened at $121.58 on Wednesday. The firm has a market cap of $1.12 billion, a PE ratio of 29.81 and a beta of 0.42. The company’s 50 day simple moving average is $113.25 and its 200-day simple moving average is $108.46. VanEck Pharmaceutical ETF has a 12-month low of $95.90 and a 12-month high of $123.53.
VanEck Pharmaceutical ETF Cuts Dividend
The firm also recently declared a quarterly dividend, which was paid on Tuesday, October 6th. Investors of record on Thursday, October 1st were paid a dividend of $0.36 per share. The ex-dividend date was Thursday, October 1st. This represents a $1.44 dividend on an annualized basis and a yield of 1.2%. This is a decrease from VanEck Pharmaceutical ETF’s previous quarterly dividend of $0.6248.
VanEck Pharmaceutical ETF Profile
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
See Also
- Five stocks we like better than VanEck Pharmaceutical ETF
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Want to see what other hedge funds are holding PPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report).
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.
